AAPL338.11+1.11 (+0.33%) ▲|ABBV263.19-0.82 (-0.31%) ▼|ABT102.26+0.03 (+0.03%) ▲|ACN185.30-4.98 (-2.62%) ▼|ADBE249.24-3.43 (-1.36%) ▼|AMAT428.38+10.98 (+2.63%) ▲|AMD547.76+2.67 (+0.49%) ▲|AMGN382.29+2.51 (+0.66%) ▲|AMT174.00-1.62 (-0.92%) ▼|AMZN252.53+1.34 (+0.53%) ▲|AVGO360.56+13.26 (+3.82%) ▲|AXP309.73-1.75 (-0.56%) ▼|BA197.61+0.55 (+0.28%) ▲|BAC57.79-0.38 (-0.65%) ▼|BKNG169.71-0.81 (-0.48%) ▼|BLK1,047.92-5.84 (-0.55%) ▼|BMY62.43-0.41 (-0.64%) ▼|BNY152.74-0.30 (-0.19%) ▼|BRK-B507.43-1.68 (-0.33%) ▼|C132.18-0.52 (-0.39%) ▼|CAT808.88+10.43 (+1.31%) ▲|CL87.26-0.47 (-0.54%) ▼|CMCSA22.58-0.34 (-1.46%) ▼|COF201.89-0.10 (-0.05%) ▼|COP133.10-0.11 (-0.08%) ▼|COST894.23+0.30 (+0.03%) ▲|CRM240.73-2.31 (-0.95%) ▼|CSCO110.43+0.19 (+0.18%) ▲|CVS88.98-1.29 (-1.43%) ▼|CVX211.72+0.13 (+0.06%) ▲|DE685.41-0.20 (-0.03%) ▼|DHR212.02-0.49 (-0.23%) ▼|DIS103.56-1.78 (-1.69%) ▼|DUK117.40-1.16 (-0.98%) ▼|EMR148.09+0.70 (+0.47%) ▲|FDX304.81-1.09 (-0.35%) ▼|GD355.30-0.63 (-0.18%) ▼|GE311.50-2.11 (-0.67%) ▼|GEV946.50+21.15 (+2.29%) ▲|GILD151.48+0.59 (+0.39%) ▲|GM84.95-1.65 (-1.91%) ▼|GOOG351.70+8.02 (+2.33%) ▲|GOOGL355.65+8.32 (+2.40%) ▲|GS946.13-4.99 (-0.52%) ▼|HD298.82-3.70 (-1.22%) ▼|HON205.94-0.55 (-0.27%) ▼|IBM233.44-4.37 (-1.84%) ▼|INTC109.72+0.92 (+0.85%) ▲|INTU306.83-6.31 (-2.01%) ▼|ISRG393.49+9.95 (+2.59%) ▲|JNJ268.02-2.20 (-0.81%) ▼|JPM346.15-3.10 (-0.89%) ▼|KO87.87-0.20 (-0.22%) ▼|LIN455.21-3.28 (-0.71%) ▼|LLY1,150.60-1.72 (-0.15%) ▼|LMT535.00-2.96 (-0.55%) ▼|LOW192.76-1.37 (-0.70%) ▼|LRCX279.23+9.92 (+3.68%) ▲|MA564.08-1.68 (-0.30%) ▼|MCD248.09-0.39 (-0.16%) ▼|MDLZ60.80-1.25 (-2.01%) ▼|MDT92.40-0.41 (-0.44%) ▼|META672.81-9.51 (-1.39%) ▼|MMM164.09-0.64 (-0.39%) ▼|MO69.27-0.43 (-0.62%) ▼|MRK146.53-0.60 (-0.41%) ▼|MS202.12-1.36 (-0.67%) ▼|MSFT493.74-4.01 (-0.81%) ▼|MU990.46+12.96 (+1.33%) ▲|NEE80.64-0.62 (-0.76%) ▼|NFLX71.37-3.94 (-5.23%) ▼|NKE36.22-0.17 (-0.46%) ▼|NOW137.07-1.43 (-1.03%) ▼|NVDA219.73+0.39 (+0.18%) ▲|ORCL146.68-3.90 (-2.59%) ▼|PEP130.19-3.47 (-2.60%) ▼|PFE27.45-0.19 (-0.69%) ▼|PG146.33-1.18 (-0.80%) ▼|PLTR172.84-3.40 (-1.93%) ▼|PM188.19-2.33 (-1.22%) ▼|QCOM187.44-1.27 (-0.67%) ▼|RTX192.73-0.81 (-0.42%) ▼|SBUX95.45-1.22 (-1.26%) ▼|SCHW104.80+0.17 (+0.16%) ▲|SO85.91-0.85 (-0.98%) ▼|SPG203.48-0.99 (-0.48%) ▼|T25.35-0.04 (-0.16%) ▼|TMO657.36-1.34 (-0.20%) ▼|TMUS165.60-0.85 (-0.51%) ▼|TSLA369.71+3.51 (+0.96%) ▲|TXN261.94+3.80 (+1.47%) ▲|UBER70.36-0.51 (-0.72%) ▼|UNH374.12-1.09 (-0.29%) ▼|UNP279.19-3.30 (-1.17%) ▼|UPS99.33-0.84 (-0.84%) ▼|USB59.97-0.29 (-0.47%) ▼|V368.04-1.89 (-0.51%) ▼|VZ47.71-0.63 (-1.29%) ▼|WFC86.27-0.62 (-0.71%) ▼|WMT107.63+0.84 (+0.79%) ▲|XOM162.59-0.68 (-0.42%) ▼|AAPL338.11+1.11 (+0.33%) ▲|ABBV263.19-0.82 (-0.31%) ▼|ABT102.26+0.03 (+0.03%) ▲|ACN185.30-4.98 (-2.62%) ▼|ADBE249.24-3.43 (-1.36%) ▼|AMAT428.38+10.98 (+2.63%) ▲|AMD547.76+2.67 (+0.49%) ▲|AMGN382.29+2.51 (+0.66%) ▲|AMT174.00-1.62 (-0.92%) ▼|AMZN252.53+1.34 (+0.53%) ▲|AVGO360.56+13.26 (+3.82%) ▲|AXP309.73-1.75 (-0.56%) ▼|BA197.61+0.55 (+0.28%) ▲|BAC57.79-0.38 (-0.65%) ▼|BKNG169.71-0.81 (-0.48%) ▼|BLK1,047.92-5.84 (-0.55%) ▼|BMY62.43-0.41 (-0.64%) ▼|BNY152.74-0.30 (-0.19%) ▼|BRK-B507.43-1.68 (-0.33%) ▼|C132.18-0.52 (-0.39%) ▼|CAT808.88+10.43 (+1.31%) ▲|CL87.26-0.47 (-0.54%) ▼|CMCSA22.58-0.34 (-1.46%) ▼|COF201.89-0.10 (-0.05%) ▼|COP133.10-0.11 (-0.08%) ▼|COST894.23+0.30 (+0.03%) ▲|CRM240.73-2.31 (-0.95%) ▼|CSCO110.43+0.19 (+0.18%) ▲|CVS88.98-1.29 (-1.43%) ▼|CVX211.72+0.13 (+0.06%) ▲|DE685.41-0.20 (-0.03%) ▼|DHR212.02-0.49 (-0.23%) ▼|DIS103.56-1.78 (-1.69%) ▼|DUK117.40-1.16 (-0.98%) ▼|EMR148.09+0.70 (+0.47%) ▲|FDX304.81-1.09 (-0.35%) ▼|GD355.30-0.63 (-0.18%) ▼|GE311.50-2.11 (-0.67%) ▼|GEV946.50+21.15 (+2.29%) ▲|GILD151.48+0.59 (+0.39%) ▲|GM84.95-1.65 (-1.91%) ▼|GOOG351.70+8.02 (+2.33%) ▲|GOOGL355.65+8.32 (+2.40%) ▲|GS946.13-4.99 (-0.52%) ▼|HD298.82-3.70 (-1.22%) ▼|HON205.94-0.55 (-0.27%) ▼|IBM233.44-4.37 (-1.84%) ▼|INTC109.72+0.92 (+0.85%) ▲|INTU306.83-6.31 (-2.01%) ▼|ISRG393.49+9.95 (+2.59%) ▲|JNJ268.02-2.20 (-0.81%) ▼|JPM346.15-3.10 (-0.89%) ▼|KO87.87-0.20 (-0.22%) ▼|LIN455.21-3.28 (-0.71%) ▼|LLY1,150.60-1.72 (-0.15%) ▼|LMT535.00-2.96 (-0.55%) ▼|LOW192.76-1.37 (-0.70%) ▼|LRCX279.23+9.92 (+3.68%) ▲|MA564.08-1.68 (-0.30%) ▼|MCD248.09-0.39 (-0.16%) ▼|MDLZ60.80-1.25 (-2.01%) ▼|MDT92.40-0.41 (-0.44%) ▼|META672.81-9.51 (-1.39%) ▼|MMM164.09-0.64 (-0.39%) ▼|MO69.27-0.43 (-0.62%) ▼|MRK146.53-0.60 (-0.41%) ▼|MS202.12-1.36 (-0.67%) ▼|MSFT493.74-4.01 (-0.81%) ▼|MU990.46+12.96 (+1.33%) ▲|NEE80.64-0.62 (-0.76%) ▼|NFLX71.37-3.94 (-5.23%) ▼|NKE36.22-0.17 (-0.46%) ▼|NOW137.07-1.43 (-1.03%) ▼|NVDA219.73+0.39 (+0.18%) ▲|ORCL146.68-3.90 (-2.59%) ▼|PEP130.19-3.47 (-2.60%) ▼|PFE27.45-0.19 (-0.69%) ▼|PG146.33-1.18 (-0.80%) ▼|PLTR172.84-3.40 (-1.93%) ▼|PM188.19-2.33 (-1.22%) ▼|QCOM187.44-1.27 (-0.67%) ▼|RTX192.73-0.81 (-0.42%) ▼|SBUX95.45-1.22 (-1.26%) ▼|SCHW104.80+0.17 (+0.16%) ▲|SO85.91-0.85 (-0.98%) ▼|SPG203.48-0.99 (-0.48%) ▼|T25.35-0.04 (-0.16%) ▼|TMO657.36-1.34 (-0.20%) ▼|TMUS165.60-0.85 (-0.51%) ▼|TSLA369.71+3.51 (+0.96%) ▲|TXN261.94+3.80 (+1.47%) ▲|UBER70.36-0.51 (-0.72%) ▼|UNH374.12-1.09 (-0.29%) ▼|UNP279.19-3.30 (-1.17%) ▼|UPS99.33-0.84 (-0.84%) ▼|USB59.97-0.29 (-0.47%) ▼|V368.04-1.89 (-0.51%) ▼|VZ47.71-0.63 (-1.29%) ▼|WFC86.27-0.62 (-0.71%) ▼|WMT107.63+0.84 (+0.79%) ▲|XOM162.59-0.68 (-0.42%) ▼|
23.5 C
New York
Friday, September 18, 2026

Tag: data

newssourceFORcompanyinformationcontent1releasesmarket

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DV

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers – FTRE

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. ("Fortrea" or the...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. – PTCT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT).  Such...

“The Most Important Thing About Art is Freedom,” says AR Rahman at IGF London 2025

Oscar-winning composer on scent cinema, AI, and the reinvention of Indian music culture LONDON, June 22, 2025 /PRNewswire/ --  In a deeply personal and expansive...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

Jason Yang and Ruoqi Li Featured In XYZ Media’s “Next Generation of Innovators” Series for Developing an AI-Driven Multimodal Model Advancing Elderly Fall Risk...

LOS ANGELES, June 22, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is proud to announce the latest feature in its “Next Generation of Innovators” series, a digital campaign celebrating extraordinary young minds developing innovative solutions to global challenges. The latest series highlights two exceptional student researchers - Jason Yang of Head-Royce School in Oakland, CA, and Ruoqi Li of The Harker School in San Jose, CA - for their novel work in developing a multimodal machine learning framework that accurately assesses fall risk among the elderly using sensors, video, and contextual data.

Analyzing U.S. Household Electricity Price Increases—Strategic Implications for Stakeholders

Electricity prices are escalating rapidly for U.S. households, despite a general cooling in overall inflation. The consumer price index for May 2025 indicated a...

Strategic Nest Egg Deployment for Optimal Retirement Income

The inquiry presents a classic challenge faced by many retirees: seeking maximum income with minimal risk. The financial landscape requires a disciplined approach, especially...

SK Group and AWS Team Up to Build Cloud Computing Infrastructure to Support AI Innovation

SK Group, in partnership with AWS, will provide data center infrastructure for a new AWS AI Zone location in Ulsan that will support AI...

‘Superintelligence’? Pipe Dream or Just More Hot Air?

Meta is making waves in the AI arena by investing in Scale AI and launching a superintelligence research lab. They're trying to catch up...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsData

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers